HiveProspectStranded Biotech Asset IntelligenceResearch intelligence
Research workspace tools

Find → Understand → Decide

Pembrolizumab/Vibostolimab

Discovery priority: MEDIUM · POSSIBLE / INVESTIGATE

Discovery priority ≠ investment recommendation. These are observation labels, not verified canonical products. Buyer qualification: UNKNOWN.

Why investigate?

Why stranded (event context): efficacy failure; inadequate public evidence; strategic reprioritization

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN

Biology implicated: UNCLEAR · Failure context: MIXED

MODEL INFERENCE · LOW confidence. Explicit asset-linked program event or documented experimental trial arm, stop scope, dated recency and biological cautions; no publication count or buyer-gate input.

Current control: UNKNOWN · Restart: UNKNOWN · Development reuse: UNKNOWN

Next diligence: Confirm present program status and exact product identity, then trace scoped rights/data/CMC and review arm-level human outcomes.

Existing buyer gates

Human Signal: UNKNOWN

Cheap Truth: UNKNOWN

Clean Rights: UNKNOWN

Market Pull: UNKNOWN

No event or publication count supplies missing gate evidence. Existing reviewed opportunities remain in their original records.

Evidence timeline

2026-09-10 · trial:NCT05665595

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

Business Reason

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "4e518caf93ee6c355ffd22143f080f928359ec6c1b18d2c6f4549f752472b5c0",
  "metadata": {
    "complete": false,
    "content_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
    "failed": false,
    "last_checked": 1790026980.9308648,
    "last_success": 1790026980.9308648,
    "live_verified": true,
    "scope": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
  "raw_path": "research/obz7_sources/79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT05665595"
}

2026-09-11 · trial:NCT05226598

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support any registration, was issued; therefore, an abbreviated CSR was generated.

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: efficacy failure · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "eb509c7b276223992db8e428ccca492cb1f8740c9da3cb5117d16ea948d1baa7",
  "metadata": {
    "complete": false,
    "content_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
    "failed": false,
    "last_checked": 1790026980.9308648,
    "last_success": 1790026980.9308648,
    "live_verified": true,
    "scope": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
  "raw_path": "research/obz7_sources/79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT05226598"
}

2026-09-17 · trial:NCT04738487

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

Business Reasons

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: strategic reprioritization · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "c0ddea6af6879b707ea900c8ef6f114cd2ac31b4631f7efb636937a53cafdde0",
  "metadata": {
    "complete": false,
    "content_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
    "failed": false,
    "last_checked": 1790026980.9308648,
    "last_success": 1790026980.9308648,
    "live_verified": true,
    "scope": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
  "raw_path": "research/obz7_sources/79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT04738487"
}

Freshness is claim-specific

Fetching an old filing today does not establish current ownership or program status.

pipeline · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

sec · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

rights · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

contact · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

patent_assignment · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

clinicaltrials · STALE · AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:00.930865+00:00

clinicaltrials · STALE · AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:00.930865+00:00

clinicaltrials · STALE · AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:00.930865+00:00

Registry observations (3)

NCT04738487 · TERMINATED · PHASE3 · Lung Neoplasms; Non-Small-Cell Lung Carcinoma · Trial sponsor Merck Sharp & Dohme LLC

Reported aliases: MK-7684A. Identity, treatment role and exposure require review.

NCT05226598 · TERMINATED · PHASE3 · Metastatic Non-Small Cell Lung Cancer · Trial sponsor Merck Sharp & Dohme LLC

Reported aliases: MK-7684A. Identity, treatment role and exposure require review.

NCT05665595 · TERMINATED · PHASE3 · Melanoma · Trial sponsor Merck Sharp & Dohme LLC

Reported aliases: MK-7684A. Identity, treatment role and exposure require review.

Back to discovery